HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
HUTCHMED (China) Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$14.18+0.13 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
HUTCHMED (China) Ltd revenue by segment
By business segment
| Revenue | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Commercial Platform | $188.86M | $189.05M | $182.79M | $177.93M | $176.46M | 92.2% | +7.0% |
| Innovation Platform | $16.03M | $15.60M | $31.33M | $36.01M | $37.65M | 7.8% | -57.4% |
By product or service
| Revenue | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Invoiced Goods-Distribution | $175.51M | – | – | – | $161.22M | 85.7% | +8.9% |
| Services | $18.61M | $21.60M | $27.79M | $31.78M | $37.17M | 9.1% | -49.9% |
| Licenses | – | – | – | – | $12.14M | – | – |
By region
From the segment and revenue-disaggregation notes of HUTCHMED (China)'s 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.